2017: A catalyst for PTX?, page-3

Great post ams71.In the case of the AML test it seems they are evaluating each patient at the end of their trial,bearing in mind they are they are recruiting 15-18 patients for the trial.It will be interesting how often we are updated as the we know there is an intense interest in these trials being shown.
The longer the trial goes the inference is that in terms of safety and tolerability it is overcoming these hurdles.We have had the independent regulatory endorsement from the FDA and we have the best of the breed scientific team in charge of the trial so it would not be expected that the trial would be discontinued...but they are testing for safety.So as the trial proceeds though to the conclusion then the speculation mounts on its efficacy...all early days and out of our hands as investors but I wish and hope for success all round